{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:16:13Z","timestamp":1742012173880,"version":"3.38.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,15]]},"DOI":"10.2169\/internalmedicine.3988-24","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:10:44Z","timestamp":1723068644000},"page":"887-891","source":"Crossref","is-referenced-by-count":0,"title":["Cancer of Unknown Primary Presenting with Chylothorax"],"prefix":"10.2169","volume":"64","author":[{"given":"Emi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"},{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneyoshi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Terao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. in: NCCN clinical practice guidelines in oncology [Internet]. [cited 2024 Mar 2]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Qaseem A, Usman N, Jayaraj JS, Janapala RN, Kashif T. Cancer of unknown primary: a review on clinical guidelines in the development and targeted management of patients with the unknown primary site. Cureus 11: e5552, 2019.","DOI":"10.7759\/cureus.5552"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Riley LE, Ataya A. Clinical approach and review of causes of a chylothorax. Respir Med 157: 7-13, 2019.","DOI":"10.1016\/j.rmed.2019.08.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Conner JR, Hornick JL. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry. Adv Anat Pathol 22: 149-167, 2015.","DOI":"10.1097\/PAP.0000000000000069"},{"key":"5","unstructured":"5. Guidelines for the Treatment of Carcinoma of Unknown Primary. 2nd ed. Nihon Rinsyou Syuyou Gakkai, Ed. Nankodo, Tokyo, 2018: 58-61."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Huebner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin <i>vs<\/i> gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 100: 44-49, 2009.","DOI":"10.1038\/sj.bjc.6604818"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tanizaki J, Yonemori K, Akiyoshi K, et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 33: 216-226, 2022.","DOI":"10.1016\/j.annonc.2021.11.009"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Canon J, Rex K, Saiki AY, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575: 217-223, 2019.","DOI":"10.1038\/s41586-019-1694-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ai Q, Li F, Zou S, et al. Targeting KRAS<sup>G12V<\/sup> mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors. Front Immunol 14: 1161538, 2023.","DOI":"10.3389\/fimmu.2023.1161538"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Haigis KM. KRAS alleles: The devil is in the detail. Trends Cancer 3: 686-697, 2017.","DOI":"10.1016\/j.trecan.2017.08.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Losa F, Fern\u00e1ndez I, Etxaniz O, et al. SEOM-GECOD clinical guideline for unknown primary cancer (2021). Clin Transl Oncol 24: 681-692, 2022.","DOI":"10.1007\/s12094-022-02806-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kr\u00e4mer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34: 228-246, 2023.","DOI":"10.1016\/j.annonc.2022.11.013"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Agrawal A, Chaddha U, Kaul V, Desai A, Gillaspie E, Maldonado F. Multidisciplinary management of chylothorax. Chest 162: 1402-1412, 2022.","DOI":"10.1016\/j.chest.2022.06.012"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sriram K, Meguid RA, Meguid MM. Nutritional support in adults with chyle leaks. Nutrition 32: 281-286, 2016.","DOI":"10.1016\/j.nut.2015.08.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ur Rehman K, Sivakumar P. Non-traumatic chylothorax: diagnostic and therapeutic strategies. Breathe (Sheff) 18: 210163, 2022.","DOI":"10.1183\/20734735.0163-2021"},{"key":"16","unstructured":"16. Hanaoka N, Nagao H, Murakami T, Chijiwa T, Suganuma T. A case of follicular lymphoma with onset of chylothorax. Nihon Kokyuki Gakkai Zasshi (J Jpn Respir Soc) 45: 31-35, 2007 (in Japanese)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_3988-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:31:23Z","timestamp":1742009483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_3988-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3988-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"article-number":"3988-24"}}